On Nov 08, major Wall Street analysts update their ratings for $McKesson (MCK.US)$, with price targets ranging from $612 to $688.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $612.
BofA Securities analyst Allen Lutz maintains with a buy rating, and adjusts the target price from $635 to $680.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $668.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $630 to $680.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $652 to $651.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The company's shares saw a 5% increase following a strong performance that addressed concerns regarding long-term target risks.
The firm highlighted that McKesson displayed robust performance across all segments with a particularly strong second-quarter showing in US Pharma. It was also noted that the guidance's midpoint suggests an encouraging acceleration in segment EBIT for fiscal year 25.
McKesson has addressed several issues and eliminated a number of significant uncertainties. The company, along with its peers, has consistently reported positive updates. Furthermore, large-cap healthcare stocks are currently rather undervalued and not widely held. There appears to be no compelling reason why the company would not revert to its recently higher valuation multiples.
Here are the latest investment ratings and price targets for $McKesson (MCK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$麥克森 (MCK.US)$的評級，目標價介於612美元至688美元。
摩根士丹利分析師Erin Wright維持買入評級，維持目標價612美元。
美銀證券分析師Allen Lutz維持買入評級，並將目標價從635美元上調至680美元。
巴克萊銀行分析師Stephanie Davis維持買入評級，維持目標價668美元。
Evercore分析師Elizabeth Anderson CFA維持買入評級，並將目標價從630美元上調至680美元。
TD Cowen分析師Charles Rhyee維持買入評級，並將目標價從652美元下調至651美元。
此外，綜合報道，$麥克森 (MCK.US)$近期主要分析師觀點如下：
公司股票在表現強勁的情況下出現了5%的增長，解決了關於長期目標風險的擔憂。
公司強調麥克森在所有板塊都表現出色，尤其是美國製藥業務在第二季度有着強勁的表現。還指出，指導的中點表明在2025財年，板塊EBIt存在令人鼓舞的加速。
麥克森已經解決了幾個問題，消除了一些重大的不確定性。與同行一起，該公司一直髮布積極的更新。此外，大市值醫療保健股目前相當被低估且不廣泛持有。看起來沒有令人信服的理由公司爲何不會恢復至最近較高的估值倍數。
以下爲今日7位分析師對$麥克森 (MCK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
